Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Technology appraisal
Reference number: TA976
Published:
Please note, this appraisal has been scheduled as a single technology appraisal and will not be part of ID6234 at this time. If this changes, we will update stakeholders and the topic webpage.